NYSE · HNGE
Hinge Health, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for HNGE: Nov 02, 2026
Hinge Health, Inc. Class A Common Stock is expected to report earnings on 11/02/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $0.27. The reported EPS for the same quarter last year was $-0.02.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.27 | $0.31 | $0.23 | 2 |
| Dec 2026 | $0.33 | $0.37 | $0.28 | 2 |
| Mar 2027 | $0.25 | $0.30 | $0.20 | 2 |
| Jun 2027 | $0.34 | $0.38 | $0.31 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · BNK Invest · RTTNews · MarketBeat- Zacks · Oct 29, 12:24 PM EDTReasons to Hold Hinge Health Stock in Your Portfolio for NowHNGE's strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.
- BNK Invest · Oct 22, 6:38 AM EDTHinge Health Reaches Analyst Target PriceIn recent trading, shares of Hinge Health Inc (Symbol: HNGE) have crossed above the average analyst 12-month target price of $111.65, changing hands for $112.00/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v
- RTTNews · Oct 13, 5:58 AM EDTBiotech Stocks At 52-Week Highs – RTSN Rises With IPO, BIIB, CON, HNGE, HSTM(RTTNews) – The following biotech stocks reached a 52-week high on October 12, 2026, driven by catalysts such as achieving promising clinical data or a public offering.
- RTTNews · Oct 5, 4:26 AM EDTBiotech Stocks At 52-Week Highs – CDNA, RCEL, AZTA, HNGE(RTTNews) – The following biotech stocks reached a 52-week high on October 2, 2026, driven by key catalysts such as encouraging quarterly reports.
- RTTNews · Oct 1, 5:04 AM EDTBiotech Stocks At 52-Week Highs – PGEN, EXEL, TWST, HNGE, PBYI(RTTNews) – The following biotech stocks reached a 52-week high on September 30, 2026, driven by key catalysts such as promising results from clinical trials.
- MarketBeat · Sep 28, 11:30 AM EDT3 Healthcare Stocks Showing Why the Sector Still Has MomentumThe healthcare sector has performed fairly well so far in 2026 due to several factors: GLP-1 medications continue to drive new business and interest, while groundbreaking AI applications help enhance and accelerate the drug discovery process. On top of that, potential mergers an
- The Motley Fool · Sep 4, 11:20 AM EDTHinge Health Director Kristina Leslie Sells 1,200 Shares for $105,876The transaction reduced her direct equity position by 4% while maintaining a multi-million dollar stake in the company.
- Zacks · Sep 3, 11:30 AM EDTHinge Health Inc. (HNGE) Up 13.7% Since Last Earnings Report: Can It Continue?Hinge Health Inc. (HNGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- MarketBeat · Aug 20, 7:35 AM EDTOne Platform, Every Ailment: Hinge Health's GambleMany people know that seemingly unrelated symptoms can be connected. But in most cases, treating individual symptoms means a separate doctor visit, sometimes to different specialists, before the full picture emerges. What if it didn’t have to be that way? That’s the question th
- Zacks · Aug 19, 12:55 PM EDTHNGE Stock Surges Nearly 90% YTD: Can Its Growth Story Continue?Hinge Health's nearly 90% YTD surge is backed by 53% revenue growth, wider margins and expansion into migraine and GI care, but execution risks remain.
- Zacks · Aug 12, 1:03 PM EDTIs Hinge Health Stock a Buy as Growth Accelerates and Risks Rise?HNGE's rapid revenue growth, widening margins and higher 2026 outlook strengthen its case, but expansion raises execution risks.
- Zacks · Aug 12, 12:57 PM EDTHinge Health's Cylinder Deal Opens a $135B GI Care Growth OpportunityHNGE's $105 million Cylinder deal opens a $135 billion GI care market, adding nearly 100 clients and about 2 million lives.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Hinge Health, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.